Brazil
Egypt
Europe
Hong Kong
Malaysia
Mexico
Morocco
Philippines
Saudi Arabia
South Africa
Taiwan
Thailand
Tunisia
Turkey
UAE
USA
Vietnam
Global HQ
Press Releases
Biocon Q2FY20 Earnings Revenue at Rs 1,611 Cr, Up 17 %; EBITDA at Rs 441 Cr, Up 12%; Net Profit (excluding exceptional item) at Rs 189 Cr, Up 3%
-
Wed, 23-Oct-2019
- Posted by: Biocon Biologics
No Comments
Biocon Biologics & Just – Evotec Biologics Sign Licensing Deal for a Biosimilar Asset
-
Thu, 10-Oct-2019
- Posted by: Biocon Biologics
Biocon and Mylan Launch First Insulin Glargine Biosimilar, Semglee®, in Australia
-
Thu, 03-Oct-2019
- Posted by: Biocon Biologics
Kiran Mazumdar-Shaw Promises to Enable Universal Access to rh-Insulin by Reducing Prices to Less than 10 US cents /Day for LMICs
-
Thu, 26-Sep-2019
- Posted by: Biocon Biologics
Biocon Biologics Expands its R&D Footprint Through Acquisition
-
Tue, 24-Sep-2019
- Posted by: Biocon Biologics
Biocon’s Malaysia Insulin Glargine Manufacturing Facility Receives EU GMP Certification, Provides Fillip to its Capacity
-
Thu, 22-Aug-2019
- Posted by: Biocon Biologics
Mylan and Biocon Launch First Trastuzumab Biosimilar, Ogivri™, in Australia
-
Thu, 01-Aug-2019
- Posted by: Biocon Biologics
Biocon Q1FY20 Revenue Rs 1,490 Cr, Up 25%; EBITDA Up 51% at Rs 462 Cr; Net Profit (excluding exceptional item) Up 86% at Rs 223 Cr
-
Thu, 25-Jul-2019
- Posted by: Biocon Biologics
Health Canada Approves Biocon and Mylan’s Ogivri™, the First Trastuzumab Biosimilar, for the Treatment of HER2-Positive Breast and Gastric Cancers
-
Wed, 22-May-2019
- Posted by: Biocon Biologics
